Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
International Journal of Clinical Pharmacy
|
February 2, 2020
Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
Mayte Gil-Candel, Juan José Gascón-Cánovas, Elena Urbieta-Sanz, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|
May 5, 2016
Hypoglycemic treatment of diabetic patients in the Emergency Department
Carmen Caballero Requejo, Elena Urbieta Sanz, Abel Trujillano Ruiz, et al.
Revista Espanola De Enfermedades Digestivas
|
April 28, 2020
Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
Mayte Gil Candel, Juan José Gascón Cánovas, Elena Urbieta Sanz, et al.
International Journal of Pharmaceutical Compounding
|
December 6, 2024
Stability Assessment of Methadone Hydrochloride Oral Solution for Dispensing in Drug Addiction Centers: A Physicochemical and Microbiological Study
Mª Antonia Meroño Saura, Pablo Selvi Sabater, Mª Pilar Sánchez Piñera, et al.
International Journal of Clinical Pharmacy
|
November 15, 2025
Immunogenicity phenotypes and reversal of pharmacokinetic impact in anti-TNF-treated immune-mediated diseases: a real-world study
Rocío Guzmán-Laiz, Carles Iniesta-Navalón, Manuel Ríos-Saorín, et al.
Therapeutic Drug Monitoring
|
April 3, 2025
External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease
Carles Iniesta-Navalón, Manuel Ríos Saorín, Juan Manuel Neira-Torrecillas, et al.
Therapeutic Drug Monitoring
|
May 9, 2025
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab
Carles Iniesta-Navalón, Manuel Ríos-Saorín, Rebeca Añez-Castaño, et al.
Revista Espanola De Enfermedades Digestivas
|
July 21, 2020
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
Mayte Gil Candel, Juan José Gascón Cánovas, Rosa Gómez Espín, et al.
Revista Espanola De Enfermedades Digestivas
|
January 22, 2026
Utility of tolerance assays for real-time management of infliximab infusion reactions
Rocío Guzmán-Laiz, Carles Iniesta-Navalón, Manuel Ríos-Saorín, et al.
British Journal of Clinical Pharmacology
|
November 21, 2025
STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient
Carles Iniesta-Navalón, Manuel Ríos-Saorín, Lorena Rentero-Redondo, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
International Journal of Clinical Pharmacy
|
February 2, 2020
Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
Mayte Gil-Candel, Juan José Gascón-Cánovas, Elena Urbieta-Sanz, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|
May 5, 2016
Hypoglycemic treatment of diabetic patients in the Emergency Department
Carmen Caballero Requejo, Elena Urbieta Sanz, Abel Trujillano Ruiz, et al.
Revista Espanola De Enfermedades Digestivas
|
April 28, 2020
Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
Mayte Gil Candel, Juan José Gascón Cánovas, Elena Urbieta Sanz, et al.
International Journal of Pharmaceutical Compounding
|
December 6, 2024
Stability Assessment of Methadone Hydrochloride Oral Solution for Dispensing in Drug Addiction Centers: A Physicochemical and Microbiological Study
Mª Antonia Meroño Saura, Pablo Selvi Sabater, Mª Pilar Sánchez Piñera, et al.
International Journal of Clinical Pharmacy
|
November 15, 2025
Immunogenicity phenotypes and reversal of pharmacokinetic impact in anti-TNF-treated immune-mediated diseases: a real-world study
Rocío Guzmán-Laiz, Carles Iniesta-Navalón, Manuel Ríos-Saorín, et al.
Therapeutic Drug Monitoring
|
April 3, 2025
External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease
Carles Iniesta-Navalón, Manuel Ríos Saorín, Juan Manuel Neira-Torrecillas, et al.
Therapeutic Drug Monitoring
|
May 9, 2025
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab
Carles Iniesta-Navalón, Manuel Ríos-Saorín, Rebeca Añez-Castaño, et al.
Revista Espanola De Enfermedades Digestivas
|
July 21, 2020
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
Mayte Gil Candel, Juan José Gascón Cánovas, Rosa Gómez Espín, et al.
Revista Espanola De Enfermedades Digestivas
|
January 22, 2026
Utility of tolerance assays for real-time management of infliximab infusion reactions
Rocío Guzmán-Laiz, Carles Iniesta-Navalón, Manuel Ríos-Saorín, et al.
British Journal of Clinical Pharmacology
|
November 21, 2025
STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient
Carles Iniesta-Navalón, Manuel Ríos-Saorín, Lorena Rentero-Redondo, et al.
Page
of 2